Article Text

other Versions

PDF

Letter
Growth attenuation therapy: practice and perspectives of paediatric endocrinologists
  1. Allison J Pollock,
  2. Norman Fost,
  3. David B Allen
  1. Department of Pediatrics, University of Wisconsin, Madison, Wisconsin, USA
  1. Correspondence to Dr Allison J Pollock, Department of Pediatrics, University of Wisconsin, Madison, WI 53703, USA; apollock{at}pediatrics.wisc.edu

Statistics from Altmetric.com

For non-ambulatory children with severe physical and cognitive disabilities (SPCD), being lifted and transported become more challenging with increasing size. Reduction in length and overall size for select children with SPCD can be accomplished by growth attenuation therapy (GAT), which reduces linear growth by administering hormones (eg, oestrogen) that accelerate epiphyseal closure. There are no reliable data describing attitudes and practices of paediatric endocrinologists regarding GAT for children with SPCD.

In collaboration with the Pediatric Endocrine Society (PES), an anonymous questionnaire about GAT was emailed to PES physician members (n=1100, 92% from the USA). Responses were stripped of identifiable information. Consent was implied by responding. The study received institutional review board exemption status at the University of Wisconsin–Madison.

Two hundred and eighty-four PES members responded …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.